To include your compound in the COVID-19 Resource Center, submit it here.

FDA reviewers question Humira benefit in UC

FDA reviewers questioned whether Humira adalimumab from Abbott Laboratories (NYSE:ABT) provides a "clinically meaningful benefit" for ulcerative colitis (UC) patients given the drug's "serious" safety risks and the availability of Remicade infliximab

Read the full 329 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE